Interestingly, in mice bearing aggressive breast cancer, anti-LOXL2 monoclonal antibody AB0023 exhibited potent inhibitory effects in activated fibroblast as suggested by an 88% reduction of α-SMA+ cells by immunohistochemistry (IHC) after AB0023 treatment (Barry-Hamilton et al., 2010). This evidence concerns the gene ACTA1 and breast cancer.